{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:10:00Z","timestamp":1768705800214,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":6920,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1111\/j.1538-7836.2003.00516.x","type":"journal-article","created":{"date-parts":[[2004,11,15]],"date-time":"2004-11-15T18:21:02Z","timestamp":1100542862000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["A novel long\u2010acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation"],"prefix":"10.1016","volume":"2","member":"78","reference":[{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0010","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJM199204093261502","article-title":"Subcutaneous low\u2010molecular\u2010weight heparin compared with continuous intravenous heparin in the treatment of proximal\u2010vein thrombosis","volume":"326","author":"Hull","year":"1992","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","article-title":"Comparison of subcutaneous low\u2010molecular\u2010weight heparin with subcutaneous standard heparin in proximal deep\u2010vein thrombosis","volume":"339","author":"Prandoni","year":"1992","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0020","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","article-title":"Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low\u2010molecular\u2010weight heparin administered at home","volume":"334","author":"Koopman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A comparison of low\u2010molecular\u2010weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep\u2010vein thrombosis","volume":"344","author":"Levine","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0030","doi-asserted-by":"crossref","first-page":"176S","DOI":"10.1378\/chest.119.1_suppl.176S","article-title":"Antithrombotic therapy for venous thromboembolic disease","volume":"119","author":"Hyers","year":"2001","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0035","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio","volume":"18","author":"Hutten","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0040","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1001\/archinte.160.22.3431","article-title":"Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy","volume":"160","author":"Douketis","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep\u2010vein thrombosis after total hip replacement","volume":"344","author":"Turpie","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0050","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0055","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip\u2010fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0060","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip\u2010replacement surgery: a randomised double\u2010blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0065","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip\u2010replacement surgery: a randomised double\u2010blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0070","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long\u2010acting pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(98)04298-6","article-title":"Deep\u2010vein thrombosis","volume":"353","author":"Lensing","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0080","first-page":"127","article-title":"Surrogate endpoints for the assessment of efficacy in venous thromboembolism treatment trials","volume":"28","author":"Lensing","year":"1998","journal-title":"Haemostasis"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0038-1656357","article-title":"Ventilation\u2010perfusion lung\u2010scanning and the diagnosis of pulmonary\u2010embolism\u2014improvement of observer agreement by the use of a lung segment reference chart","volume":"68","author":"Lensing","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0090","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/01.CIR.102.22.2726","article-title":"Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A\/Org31540) with pure anti\u2010factor Xa activity","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0049-3848(77)90150-5","article-title":"Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified anti\u2010thrombin III","volume":"10","author":"Teien","year":"1977","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0100","unstructured":"Committee for proprietary medicinal products (CPMP). Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Venous Thromboembolic Disease; CPMP\/EWP\/563\/98; date for coming into operation, June 2000; http:\/\/www.eudra.org\/emea.html"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002512-199914040-00005","article-title":"Safety of treatment with oral anticoagulants in the elderly. A systematic review","volume":"14","author":"Hutten","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0037-1614412","article-title":"Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis","volume":"81","author":"Lopaciuk","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2003.00516.x_bb0115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00063198-200007000-00013","article-title":"Long\u2010term treatment of venous thromboembolism with low\u2010molecular\u2010weight heparin","volume":"6","author":"Monreal","year":"2000","journal-title":"Curr Opin Pulmon Med"}],"updated-by":[{"DOI":"10.1111\/j.1538-7836.2004.00717.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000}}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2003.00516.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622177858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622177858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2003.00516.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T05:22:56Z","timestamp":1673846576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622177858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S1538783622177858"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2003.00516.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel long\u2010acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2003.00516.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}